| dbo:abstract
|
- Locus Biosciences is a clinical-stage pharmaceutical company, founded in 2015 and based in Research Triangle Park, North Carolina. Locus develops phage therapies based on CRISPR–Cas3 gene editing technology, as opposed to the more commonly used CRISPR-Case9, delivered by engineered bacteriophages. The intended therapeutic targets are antibiotic-resistant bacterial infections. (en)
|
| dbo:foundingDate
| |
| dbo:foundingYear
| |
| dbo:industry
| |
| dbo:locationCity
| |
| dbo:numberOfEmployees
|
- 80 (xsd:nonNegativeInteger)
|
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 16998 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:brands
| |
| dbp:founded
| |
| dbp:founders
|
- (en)
- Nick Taylor (en)
- Ahmed Gomaa (en)
- Rodolphe Barrangou (en)
- Charles Gersbach (en)
- Chase Beisel (en)
- Dave Ousterout (en)
- Paul Garofolo (en)
|
| dbp:hqLocationCity
|
- Morrisville, North Carolina (en)
|
| dbp:hqLocationCountry
| |
| dbp:industry
| |
| dbp:logo
|
- Locus Biosciences logo.png (en)
|
| dbp:name
| |
| dbp:numEmployees
| |
| dbp:numEmployeesYear
| |
| dbp:type
|
- Privately held company (en)
|
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Locus Biosciences is a clinical-stage pharmaceutical company, founded in 2015 and based in Research Triangle Park, North Carolina. Locus develops phage therapies based on CRISPR–Cas3 gene editing technology, as opposed to the more commonly used CRISPR-Case9, delivered by engineered bacteriophages. The intended therapeutic targets are antibiotic-resistant bacterial infections. (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| foaf:name
| |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
_logo.png=3fwidth=3d300){kind=logo}
_logo.png){kind=link}
